Replies to post #239446 on Biotech Values

[DewDiligence]

APLS submits NDA in dry AMD despite_missing_primary_endpoint in one of two phase-3 trials (#msg-165847030):

https://www.globenewswire.com/news-release/2022/06/01/2454084/0/en/Apellis-Announces-Submission-of-New-Drug-Application-to-the-FDA-for-Pegcetacoplan-for-Geographic-Atrophy.html

Please see #msg-161836649 for related info.